Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections
Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections
复制标题
DOI：
10.1017/s003118201300142x
复制
发表时间：
2014-01-01
期刊：
影响因子：
2.4
通讯作者：
Ioset, Jean-Robert
中科院分区：
文献类型：
--
作者：
Don, Rob;Ioset, Jean-Robert
被忽视疾病药物计划（DNDi）在过去几年中定义并实施了一项早期发现战略，以适应其虚拟研发业务模式。该策略依赖于中高通量表型分析平台，以加快筛选通过与制药行业合作伙伴合作获得的化合物文库。我们回顾了务实的方法来选择化合物库对动质体筛选，考虑到筛选能力。在确定新的质量系列进一步发展成临床前候选人的优势，局限性和目前的成就进行了严格的讨论，连同有吸引力的新方法，目前正在调查。
The Drugs for Neglected Diseases initiative (DNDi) has defined and implemented an early discovery strategy over the last few years, in fitting with its virtual R&D business model. This strategy relies on a medium- to high-throughput phenotypic assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the pharmaceutical industry. We review the pragmatic approaches used to select compound libraries for screening against kinetoplastids, taking into account screening capacity. The advantages, limitations and current achievements in identifying new quality series for further development into preclinical candidates are critically discussed, together with attractive new approaches currently under investigation.